Immunologic Factors
"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
Descriptor ID |
D007155
|
MeSH Number(s) |
D27.505.696.477
|
Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 2 | 1 | 3 | 2000 | 1 | 0 | 1 | 2003 | 1 | 1 | 2 | 2005 | 2 | 1 | 3 | 2006 | 4 | 0 | 4 | 2007 | 2 | 0 | 2 | 2008 | 3 | 1 | 4 | 2009 | 9 | 3 | 12 | 2010 | 3 | 2 | 5 | 2011 | 4 | 4 | 8 | 2012 | 5 | 1 | 6 | 2013 | 8 | 2 | 10 | 2014 | 6 | 1 | 7 | 2015 | 6 | 1 | 7 | 2016 | 5 | 6 | 11 | 2017 | 4 | 3 | 7 | 2018 | 8 | 1 | 9 | 2019 | 8 | 3 | 11 | 2020 | 7 | 7 | 14 | 2021 | 4 | 3 | 7 | 2022 | 2 | 8 | 10 | 2023 | 0 | 1 | 1 | 2024 | 0 | 5 | 5 | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Corboy JR, Fox RJ, Cutter G, Engebretson E, Miller A, Morgan C, Gustafson T, Goodman AD, Kannan M, Sriram S, Xia Z, Lynch S, Bowen J, Kister I. DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial. Mult Scler. 2025 Feb; 31(2):159-173.
-
Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15; 272(2):137.
-
Virupakshaiah A, Schoeps VA, Race J, Waltz M, Sharayah S, Nasr Z, Moseley CE, Zamvil SS, Gaudioso C, Schuette A, Casper TC, Rose J, Flanagan EP, Rodriguez M, Tillema JM, Chitnis T, Gorman MP, Graves JS, Benson LA, Rensel M, Abrams A, Krupp L, Lotze TE, Aaen G, Wheeler Y, Schreiner T, Waldman A, Chong J, Mar S, Waubant E. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024 Dec 16; 96(1):68-75.
-
Abbott KS, Palestine AG, Hauswirth SG, Gregory DG, Patnaik JL, Reddy AK. Treatment of Ocular Surface Disease in Ocular Cicatricial Pemphigoid. Ocul Immunol Inflamm. 2024 Dec; 32(10):2479-2485.
-
Gross RH, Corboy J. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2024 Sep; 24(9):341-353.
-
Nasr Z, Casper TC, Waltz M, Virupakshaiah A, Lotze T, Shukla N, Chitnis T, Gorman M, Benson LA, Rodriguez M, Tillema JM, Krupp L, Schreiner T, Mar S, Rensel M, Rose J, Liu C, Guye S, Manlius C, Waubant E. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab. Mult Scler Relat Disord. 2024 Jul; 87:105647.
-
Johnson TS, MacDonald TJ, Pacholczyk R, Aguilera D, Al-Basheer A, Bajaj M, Bandopadhayay P, Berrong Z, Bouffet E, Castellino RC, Dorris K, Eaton BR, Esiashvili N, Fangusaro JR, Foreman N, Fridlyand D, Giller C, Heger IM, Huang C, Kadom N, Kennedy EP, Manoharan N, Martin W, McDonough C, Parker RS, Ramaswamy V, Ring E, Rojiani A, Sadek RF, Satpathy S, Schniederjan M, Smith A, Smith C, Thomas BE, Vaizer R, Yeo KK, Bhasin MK, Munn DH. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. Neuro Oncol. 2024 02 02; 26(2):348-361.
-
Birnbaum LA, Sullivan EC, Do P, Uricoli B, Raikar SS, Porter CC, Henry CJ, Dreaden EC. Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines. Biomacromolecules. 2023 03 13; 24(3):1164-1172.
-
Littlefield KM, Schneider JM, Neff CP, Soesanto V, Siebert JC, Nusbacher NM, Moreno-Huizar N, Cartwright IM, Armstrong AJS, Colgen SP, Lozupone CA, Palmer BE. Elevated inflammatory fecal immune factors in men who have sex with men with HIV associate with microbiome composition and gut barrier function. Front Immunol. 2022; 13:1072720.
-
Kanchan K, Shankar G, Huffaker MF, Bahnson HT, Chinthrajah RS, Sanda S, Manohar M, Ling H, Paschall JE, Toit GD, Ruczinski I, Togias A, Lack G, Nadeau KC, Jones SM, Nepom GT, Mathias RA. HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success. Front Immunol. 2022; 13:941839.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|